Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 4

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

NCT06964113 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 4
Started
2025-06-11
Last updated
2026-07-02

Condition(s) studied

Ulcerative Colitis

Investigational drug(s) / intervention(s)

Filgotinib Maleate →

Filgotinib Maleate: Administered as oral tablets.

Study summary

The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.

Eligibility

Sex
ALL
Min age
19 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: 1. Adult participants aged 19 to 64 years at the time of written consent 2. Participants must meet both of the following conditions: i) Diagnosed with moderately to severely active ulcerative colitis as determined by the Mayo Clinic Score with endoscopy occurring during screening; total score must be between 6 and 12, inclusive and endoscopy sub-score greater than or equal to (\>=) 2 (However, if there are results of an endoscopy performed within two (2) months of the screening visit, and if NHI evaluation can be performed using the stored specimens obtained from that endoscopy, it can replace screening endoscopy.) ii) Have had an inadequate response to, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or a biologic agent based on the investigator's judgement at the screening visit. 3. Participant who is considered reliable by the investigator regarding provision of information, and is willing to comply with the study protocol procedures Exclusion Criteria: 1. Participants with hypersensitivity to the active substance or to any of the excipients listed in the approved label of filgotinib 2. Participants with active infections, including serious infections (example \[e.g.\], sepsis) or local infections 3. Participants with active tuberculosis (TB). For participants with latent tuberculosis, domestic standard anti-tuberculosis therapy must be initiated at least 3 weeks prior to the first administration of the study drug (Visit 2, Day 1). 4. Participants with severe hepatic impairment (Child-Pugh C) 5. Participants with moderate or greater renal impairment (Creatinine Clearance \[CrCl\] less than (\<) 60 milliliter per minute \[mL/min\]) 6. Participants who meet any of the following laboratory values: 7. Absolute neutrophil count (ANC) less than (\<) 1\*10\^9 cells per liter (/L) * Absolute lymphocyte count (ALC) \<0.5\*10\^9 cells/L * Hemoglobin level \<8 grams per deciliter (g/dL) * Hemoglobin level \<8 g/dL 8. Female participants who are pregnant or breastfeeding at Visit 1. Even if a pregnancy test result at Visit 1 was negative, a separate evaluation is required at Visit 2 if the first dose of the study drug was administered more than 72 hours after the pregnancy test. 9. Female participants of childbearing potential who do not agree to use one of the following highly effective methods of contraception from 4 weeks prior to Visit 1 until 4 weeks after the last dose of study drug: * Complete abstinence (if this is the preferred and usual lifestyle of the participants) * Intrauterine device or hormone-containing intrauterine system (IUS) * Contraceptive implant * Oral contraceptives (participants must be on the same oral contraceptive at a stable dose for at least 4 weeks prior to the administration of the study drug, during the study and for 4 weeks after discontinuation of the study drug) * Partner has had a vasectomy and is confirmed to be azoospermia If a highly effective method of contraception is not appropriate or acceptable for the participants, the participants must agree to use a medically acceptable method of contraception, that is (i.e.), double barrier method of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide. Note: All women will be considered to be of childbearing potential unless they are postmenopausal (at least 12 consecutive months of amenorrhea with no other known or suspected cause) or surgically sterile (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all surgically performed, at least 1 month prior to the administration of the study drug). 10. Participants with hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption 11. Participants with a history of prior treatment with Janus kinase (JAK) inhibitor 12. Participants currently participating in other clinical study or participants who used other investigational product/medical device within 4 weeks of the screening visit 13. Participants deemed inappropriate to participate in this study at the investigator's discretion.

Primary outcome measure(s)

  • Percentage of Participants Achieving Clinical Remission at Week 10 or 22 — At Week 10 or 22

Trial sites (19)

FacilityCityRegionStatus
Eisai Site #13 Busan South Korea
Eisai Site #15 Busan South Korea
Eisai Site #8 Busan South Korea
Eisai Site #6 Daegu South Korea
Eisai Site #2 Daejeon South Korea
Eisai Site #16 Gyeonggi-do South Korea
Eisai Site #4 Gyeonggi-do South Korea
Eisai Site #11 Gyeongnam South Korea
Eisai Site #18 Jungnam South Korea
Eisai Site #7 Jungnam South Korea
Eisai Site #10 Seoul South Korea
Eisai Site #12 Seoul South Korea
Eisai Site #14 Seoul South Korea
Eisai Site #17 Seoul South Korea
Eisai Site #19 Seoul South Korea
Eisai Site #1 Seoul South Korea
Eisai Site #3 Seoul South Korea
Eisai Site #5 Seoul South Korea
Eisai Site #9 Seoul South Korea

More Eisai Korea Inc. trials in South Korea

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06964113 on ClinicalTrials.gov ↗ ← All trials in South Korea